Clinical Research Directory
Browse clinical research sites, groups, and studies.
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
Sponsor: City of Hope Medical Center
Summary
Although advances in chemotherapy have improved the prognosis of gastric cancer patients, many patients still suffer from adverse events. Therefore, it is necessary to establish personalized treatment by identifying patients at high risk for side effects. Although paclitaxel-based therapy is the standard second-line treatment, peripheral neuropathy is a troublesome adverse event. The purpose of this study is to establish a liquid biopsy assay to predict paclitaxel-induced peripheral neuropathy in gastric cancer patients.
Official title: Predicting Peripheral Neuropathy of Paclitaxel in Second-line Chemotherapy for Gastric Cancer
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2018-10-01
Completion Date
2026-06-18
Last Updated
2025-07-11
Healthy Volunteers
Not specified
Interventions
Paclitaxel
Gastric cancer second-line chemotherapy
Locations (1)
Kawasaki Medical University
Kurashiki, Okayama-ken, Japan